Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00318994|
Recruitment Status : Completed
First Posted : April 27, 2006
Last Update Posted : September 1, 2017
|Condition or disease||Intervention/treatment||Phase|
|Pancreatitis||Drug: Meropenem||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||6 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis|
|Study Start Date :||February 2002|
|Actual Primary Completion Date :||September 2005|
|Actual Study Completion Date :||May 2007|
- To measure meropenem pancreatic tissue penetration in subjects with severe pancreatitis requiring surgery between 30 and 60 minutes after a bolus of 1 g IV meropenem applied during induction of anesthesia.
- To describe the incidence of infectious complications during the first 30 days after surgery in subjects with severe pancreatitis receiving IV meropenem at a dose of 1 g every 8 hours during 14 days.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00318994
|Study Director:||AstraZeneca Columbia Medical Director, MD||AstraZeneca|